KAPA

Kairos Pharma, LTD.

$0.37 +0.00 (+0.54%) At close · Jul 2

Market Cap

$7.92M

21,411,198

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-06-04	Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
2026-05-14	Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
2026-05-08	Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
2026-04-15	Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
2026-03-02	Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
2026-02-26	Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
2026-01-20	Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
2025-12-17	Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
2025-11-04	Kairos Pharma Provides Shareholder Update
2025-10-20	Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Past events

Date	Event	Type
2026-06-30	Technology Networks: The Landscape of Cancer Research: Advances in Immuno-Oncology 2026	Event
2026-04-30	Biospace, Opinion: Tackling drug resistance must become biotech’s next frontier	Event
2026-04-14	MDLinx, Drug resistance is reshaping lung cancer care—AACR 2026 may reveal what’s next	Event
2026-03-17	Emerging Therapeutic Strategies in Oncology	Event
2026-01-29	Redcap Interview of Neil Bhowmick, CSO.	Event
2025-12-02	A Further Inquiry Q&A article: ENV105 in Advanced Prostate Cancer: How Kairos Pharma Reverses Drug Resistance	Event
2025-09-22	Kairos Pharma KOL Event Regarding Phase 2 Prostate Cancer Trial Interim Data	Event
2025-09-05	Company Presentation at H.C. Wainwright 27th Annual Global Investment Conference	Conference
2025-07-27	Digital Journal Article	Event
2025-07-24	Inside the Boardroom Interview	Event
2025-07-17	Interview on Big Biz TV Show	Event
2025-06-02	ASCO Presentation	Presentation
2025-05-06	Interview on Big Biz TV Show	Event
2025-04-24	Interview on Big Biz TV Show	Event
2025-03-31	Interview on Big Biz TV Show	Event
2025-03-26	Inside the Boardroom interview: Kairos Pharma’s Breakthrough Cancer Treatment & What’s Next for ENV105	Event
2025-02-18	Kairos Pharma secures funding from Department of Defense to Advance Cancer Drug Research	Event
2025-02-06	Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma	Conference
2024-12-04	CEO.CA interview: Kairos Pharma: Creating Therapeutics to Reverse Cancer Drug Resistance	Event
2024-11-21	Mission Matters Podcast - An Unmet Need in Oncology: Drug Resistance	Event
2024-11-21	Authority Magazine: Meet the Disruptors	Event
2024-11-04	Nano Cap podcast - Reversing Cancer Drug Resistance and Immunosuppression	Event
2024-11-04	Nano Cap podcast - Personalized Medicine - Boosting Clinical Trial Success and Reducing Costs	Event
2024-11-04	Nano Cap podcast - John Yu on FDA-Approved Phase 2 Trial with Apalutamide and Biomarkers	Event
2024-11-04	Nano Cap podcast - Kairos Pharma - $KAPA	Event

Source: https://investors.kairospharma.com/overview/default.aspx

Key facts CIK 1962011 CUSIP 48301N104 Visit website Investor relations